In:
Clinical Transplantation, Wiley, Vol. 31, No. 11 ( 2017-11)
Kurzfassung:
The safety and efficacy of an IFN ‐free regimen using asunaprevir ( ASV ) and daclatasvir ( DCV ) for recurrent hepatitis C virus ( HCV ) infection after liver transplantation ( LT ) have not been evaluated in Japan. A multicenter study of LT recipients (n = 74) with recurrent HCV genotype 1b infection treated with ASV ‐ DCV for 24 weeks was performed. Medical history was positive for pegylated interferon and ribavirin (Peg‐ IFN / RBV ) in 40 (54.1%) patients, and for simeprevir ( SMV ) with Peg‐ IFN / RBV in 12 (16.2%) patients. Resistance‐associated variants ( RAV s) were positive at D168 (n = 1) in the NS 3, and at L31 (n = 4), Y93 (n = 4), and L31/Y93 (n = 1) in the NS 5A region of the HCV genome. Sixty‐one (82.4%) patients completed the 24‐week treatment protocol. Although sustained viral response ( SVR ) was achieved in 49 (80.3%) patients, it was achieved in only two (16.7%) patients among those with histories of receiving SMV (n = 12). Univariate analysis showed that a history of SMV ( P 〈 .01) and the presence of mutations in NS 5A ( P = .02) were the significant factors for no‐ SVR . By excluding the patients with either a history of SMV ‐based treatment or RAV s in NS 3/ NS 5A, the SVR rate was 96.4%. By excluding the patients with a history of SMV and those with RAV s in NS 3/ NS 5A, viral clearance of ASV ‐ DCV was favorable, with a high SVR rate.
Materialart:
Online-Ressource
ISSN:
0902-0063
,
1399-0012
DOI:
10.1111/ctr.2017.31.issue-11
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2017
ZDB Id:
2739458-X
ZDB Id:
2004801-4